Welcome Message
Welcome to the 2023 EASL Liver Cancer Summit – the home of liver cancer research and practice – that will be held in the cosy Portuguese city of Estoril.
Over the last decades, the considerable advances produced in our understanding of the pathogenesis of hepatocellular and cholangiocellular carcinoma – the two most frequent primary liver tumours – has only recently started to change the way we treat these diseases in clinical practice. Recent findings will likely soon transform the way we diagnose liver cancer, screen at risk patients, and treat patients with primary liver cancer. Keeping up to date with the most recent advances is a great challenge and an absolute need for practicing physicians and basic or translational scientists with an interest in the field. We have designed a scientific program that we believe will meet this big challenge.
To present and discuss the current knowledge and future directions in the study and management of primary liver cancer, an extraordinary group of colleagues, from various disciplines, have accepted to join you in Estoril for three days. To take advantage of this outstanding group of experts, and to allow fruitful interactions between you and your colleagues, great discussions are planned in every session of the programme.
We are convinced that this meeting will offer you a great opportunity to share your research results (the best abstracts will be presented as oral or poster presentations), meet colleagues who could collaborate in your research projects, and get to meet and know the best experts in the field.
We last met at a physical Liver Cancer Summit in Prague in 2020. Now more than ever, the EASL liver cancer community must come together again to consolidate our understanding of recent research and all that it promises, and to discuss how we as a community can leverage this potential to meaningfully reduce the burden of liver cancer worldwide. What better time and place to do this than this coming April in Estoril, Portugal.
Sincerely,
Nathalie Ganne-Carrié, Mathias Heikenwälder, and Bruno Sangro
EASL Liver Cancer Summit 2023 Organising Committee
Prof. Nathalie Ganne-Carrié
Paris, France
Nathalie Ganne-Carrié is Professor in Hepatology, head of the liver unit of the Hôpitaux Universitaires Paris Seine Saint-Denis, France (Avicenne, Bobigny) in which more than 50% of the activity is dedicated to primary liver tumor, and a clinical researcher at INSERM U1138.
Prof. Mathias Heikenwälder
Heidelberg, Germany
Prof. Heikenwälder and his group investigate the molecular and cellular mechanisms that lead to chronic inflammation, tissue damage, cancer and metastasis. In tight collaboration with clinics he is working on new models and therapy approaches. Prof. Heikenwälder studied microbiology in Vienna.
- Highly cited scientist (2020; Clarivate Cross fields)
- Highly cited scientist (2020; Clarivate Cross fields)
- Highly cited scientist (2019; Clarivate Cross fields)
- Prize of the Swiss Foundation against liver cancer
- ERC POC 2018
- ERC Consolidator Grant (2016)
- Walther und Christine Ritzenhain-Preis (2012)
- ERC Starting Grant (2010)
- Hans-Peter Hofschneider-Preis (2010)
- Götz-Preis, vergeben an der Universität Zürich, Schweiz (2009)
- Max-Cloëtta Professorship (2007)
- EMPIRIS Award (2006)
- Creutzfeld-Preis (2004)
Prof. Bruno Sangro
Pamplona, Spain
Prof. Bruno Sangro is Director of the Liver Unit and Co-Director of the HPB Oncology Area at Clínica Universidad de Navarra in Pamplona, Spain. He currently serves as Past President of the International Liver Cancer Association.
